Medical New
Clinical Inshorts delivers 1 minute daily updates on medical news.
FDA approves WAYRILZ (Rilzabrutinib) for chronic ITP in adults
The U.S. FDA approved WAYRILZ (rilzabrutinib) tablets for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded to previous treatments. MOA: kinase inhibitor Dosage: 400 mg BD…
Read More
FDA approves first generic Liraglutide for obesity treatment
The U.S. FDA approved Teva Pharmaceuticals’ generic version of liraglutide (Saxenda®), the first generic GLP-1 receptor agonist for chronic weight management. Indication: It is indicated for adults with obesity (BMI…
Read More
Atezolizumab + Bevacizumab leads in survival for advanced HCC
A new network meta-analysis of nine phase 3 trials (n=6425) compared first-line treatments for advanced hepatocellular carcinoma (HCC), focusing on overall survival (OS) and health-related quality of life (HR-QoL). Researchers…
Read More
FDA approves Papzimeos (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis
Papzimeos is the first and only FDA-approved therapy for the treatment of adults with RRP. Introduction: PAPZIMEOS™ is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with…
Read More
2025 AHA hypertension guidelines: Key updates for clinical practice
Blood Pressure Categories & Treatment Targets The guideline retains the 2017 definitions of blood pressure categories: Normal: < 120/80 mm Hg Elevated: 120–129 / < 80 mm Hg Stage 1…
Read More
Ruxolitinib outperforms best available therapy in chronic GVHD
A phase 3, randomized, open-label trial of 329 patients (≥12 years) with steroid-refractory/dependent chronic graft-vs-host disease (SR/D-cGVHD) found that ruxolitinib significantly extended median failure-free survival (FFS) to 38.4 months versus…
Read More
Enlarged thymus at 2 months linked to higher risk of Atopic Dermatitis
Infants with a larger thymus at 2 months of age had a significantly higher risk—over sixfold—for developing atopic dermatitis (AD) by age 2. The risk remained high—over fivefold—for early-onset AD…
Read More
ASTRO guidelines incorporate the 2021 WHO glioma reclassification
Glioblastoma (GBM), now classified as CNS WHO grade 4 adult-type diffuse glioma, is the most aggressive and common malignant brain tumor in adults. Despite advancements in surgery, radiation therapy (RT),…
Read More
Semaglutide emerges as a potential treatment for MASH
Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Methods: In this phase 3 trial, 1197 patients with biopsy-confirmed MASH and liver…
Read More
New guidelines prioritize Iron over Dopamine in Restless Legs Syndrome
Restless Legs Syndrome (RLS) affects 8% of the population, mainly women. It causes an overwhelming urge to move the legs, especially in the evening or during rest, often with tingling…
Read More
OMI & NOMI concept: Replacing the STEMI/NSTEMI terminologies
In 2018, Meyers, Weingart and Smith introduced us to the concept of Occlusion Myocardial Infarction (OMI). The term STEMI equivalent is already in our vocabulary, but it actually refers to…
Read More
Human Metapneumovirus (HMPV) symptoms, diagnosis & treatment
Human metapneumovirus (HMPV) is a negative-sense ss RNA virus of the family Pneumoviridae. It was isolated for the first time in 2001 in the Netherlands. It is the second most…
Read More
Indian Health Ministry approves BPaLM regimen for MDR TB
Indian Health Ministry approves introduction of new shorter and more efficacious treatment regimen for drug-resistant TB. BPaLM regimen consisting of 4 drug combination. In December 2022 WHO also released a…
Read More
Causes of sudden cardiac arrest
Causes of sudden cardiac arrest: 1. Cardiovascular pathology Coronary artery disease (MC - 80% of all cases) Severe left ventricular dysfunction 2. Cardiomyopathy (10-15% of all cases) Hypertrophic cardiomyopathy Arrhythmogenic…
Read More
FDA approves novel drug for resistant hypertension based on PRECISION trial
The USA FDA has approved Aprocitentan (Brand name TRYVIO) for the treatment of resistant hypertension in combination with other antihypertensive drugs. Dose: 12.5 mg 1OD PO. MOA: Dual endothelin receptor…
Read More
FDA approves Nivolumab for resected stage IIB/C melanoma
The US FDA has approved nivolumab for the treatment of completely resected stage IIB/C melanoma for patients aged 12 years and older, expanding the melanoma indication for the programmed death…
Read More
Ritlecitinib for severe alopecia areata by European Commission
The European Commission has approved ritlecitinib to treat adults and adolescents 12 years of age and older with severe alopecia areata. Ritlecitinib is a dual inhibitor of the TEC family…
Read More
Elon Musk’s Neuralink to start human trial of brain implant for paralysis patients
Elon Musk's brain-chip startup Neuralink has received approval to begin recruitment for the first human trial of its brain implant for paralysis patients. Those with paralysis due to cervical spinal…
Read More
FDA approves Talquetamab for multiple myeloma
The USA FDA approves Talquetamab, a first-in-class bispecific antibody targeting the GPRC5D receptor, for heavily pretreated adults with relapsed or refractory multiple myeloma. Indication for usage: Patients must have received…
Read More
Naltrexone is safe & beneficial in AUD with Cirrhosis
Naltrexone can be safely administered to patients with alcohol use disorder (AUD) and compensated cirrhosis to help them achieve abstinence and decrease craving, results of the first such randomized controlled…
Read More
FDA approves Sotagliflozin for heart failure
Sotagliflozin, a novel agent that inhibits sodium-glucose co transporter SGLT 1 & SGLT2 both as a treatment for adults with heart failure with or without diabetes and for T1DM &…
Read More
FDA approves Inj Buprenorphine for opioid use disorder
The US FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The medication comes in two formulations: a weekly…
Read More
FDA expands Atogepant approval for chronic migraine
Atogepant is the first and only, oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for migraine. Dose: 60 mg dose 1 OD in chronic migraine. 30 mg and 60 mg…
Read More
Global Strategy for Diagnosis, Management & Prevention of COPD 2023 Updates
The 2023 GOLD report contains numerous updates: Chapter 1 ► A new definition of COPD has been proposed (Page 5) ► A section on Chronic Bronchitis has been added (Page…
Read More
FDA approves Dabrafenib with Trametinib for pediatric gliomas
The US FDA has approved dabrafenib with trametinib for children aged 1 year or older who need systemic treatment for low-grade gliomas that have a BRAF V600E mutation. Dabrafenib/trametinib is…
Read More
FDA approves new drug for Hemophilia A
The US FDA has approved efanesoctocog alfa (Altuviiio), a first-in-class, high-sustained factor VIII replacement therapy for adults and children with hemophilia A. The product is used once a week and…
Read More
FDA approves sacituzumab govitecan for HR+ metastatic breast CA
The US FDA approved a new indication for sacituzumab govitecan for patients with unresectable, locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer after endocrine-based therapy and at least…
Read More
FDA approves Pirtobrutinib for R/R mantle cell lymphoma
The US FDA approved pirtobrutinib (Jaypirca) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor. Pirtobrutinib…
Read More
Two classes of drug appear effective for gastroparesis treatment
Two classes of drugs may be more effective than others for the treatment of gastroparesis, though the overall quality of evidence remains low to moderate and additional data are needed,…
Read More
FDA approves first in class drug for Follicular Lymphoma
The US FDA has approved mosunetuzumab-axgb (Lunsumio) for use in patients with relapsed or refractory follicular lymphoma who have received at least two previous systemic therapies. This is a first-in-class…
Read More
FDA approves a new drug for multi-drug resistant HIV-1
Lenacapavir is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. The drug blocks the HIV-1 virus protein shell and interferes with…
Read More
Adagrasib approved for KRAS-Mutated NSCLC
The US FDA has approved Adagrasib (Krazati) for use in adults with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) that has progressed on at least one…
Read More
ADA advises new BP, lipid targets for people with diabetes
New more aggressive targets for blood pressure and lipids are among the changes to the annual American Diabetes Association (ADA) Standards of Care in Diabetes 2023. The new definition of…
Read More
Potential new biomarker for early stage Alzheimer disease
Investigators found that levels of formic acid, a metabolic product of formaldehyde found in urine, were significantly higher in individuals with Alzheimer disease including those with subjective cognitive decline, which…
Read More
FDA approves first drug to delay type 1 diabetes onset
The US FDA has approved the anti-CD3 monoclonal antibody teplizumab-mzwv (Tzield, Provention Bio) to delay the onset of clinical type 1 diabetes in people aged 8 years and older who…
Read More
FDA approves new Immunotherapy combination for mNSCLC
The US FDA has approved a new combination of immunotherapies for use together with platinum-based chemotherapy for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) whose tumors…
Read More
GFAP & NfL may be complementary biomarkers for MS
Neurofilament light chain (NfL) is a biomarker for both disease progression and treatment response in multiple sclerosis (MS), but the search continues for additional biomarkers to distinguish between disease activity…
Read More
Vonoprazan is superior to PPI for erosive esophagitis
The oral potassium-competitive acid blocker vonoprazan was superior to the proton pump inhibitor lansoprazole for erosive esophagitis, according to results of the phase 3 PHALCON-EE trial. The 878 patients with…
Read More
FDA approves SC furosemide preparation
The US FDA has approved a furosemide preparation (Furoscix, scPharmaceuticals) intended for subcutaneous self-administration by outpatients with CHF and volume overload. The product is used with a SmartDose On-Body Infuser…
Read More
FDA approves Ibalizumab for HIV-1 treatment
Ibalizumab is a long-acting monoclonal antibody, was first approved by the FDA in 2018 for the treatment of adults with multidrug resistant HIV-1. It is used in combination with other…
Read More
FDA approves Dupilumab for treatment of Prurigo Nodularis
The US FDA has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication. MOA: Dupilumab (Dupixent), which inhibits the signaling of the interleukin 4…
Read More
Tezepelumab approved for severe uncontrolled asthma
Tezepelumab is an epithelial cytokine, and is the first and only biologic approved in Europe by EC for severe asthma for adults and adolescents with inadequately controlled severe asthma with…
Read More
(CAR) T-cell therapy treats SLE successfully
The five patients all of whom had an aggressive form of SLE underwent a single infusion of the experimental treatment. All five patients were able to stop their standard treatments…
Read More
Use of Nirsevimab against respiratory syncytial virus (RSV) in Infants
RSV is the leading cause of lower respiratory tract infections in infants. Worldwide, acute lower respiratory infections associated with RSV account for about 1.4 million hospitalizations & 27,300 in-hospital deaths…
Read More
FDA approves Terlipressin injection for Hepatorenal Syndrome
The US FDA has approved terlipressin (Terlivaz), the first and only drug approved for patients with hepatorenal syndrome (HRS). HRS is characterized by a progressive deterioration in kidney function in…
Read More
FDA approves daxibotulinumtoxinA-lanm injection for glabellar lines
The US FDA has approved daxibotulinumtoxinA-lanm injection (Daxxify) to temporarily improve the appearance of moderate to severe glabellar lines (frown lines) in adults. Action: It's an acetylcholine release inhibitor and…
Read More
FDA approves first gene therapy for Beta-Thalassemia
The US FDA has approved the gene therapy betibeglogene autotemcel (Zynteglo) for adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. Functional copies of the mutated…
Read More
A novel Langya virus infects 35 people in eastern China
A novel zoonotic RNA Langya virus (LayV) is a henipavirus first detected in the China provinces of Shandong and Henan. The name of the virus refers to Mt. Langya. Symptoms:…
Read More
Monkeypox : Signs, Symptoms & Treatment
Monkeypox is a zoonotic orthopoxvirus. Usual onset: 5–21 days post-exposure. Duration: 2 to 4 weeks. Route: Human-to-human transmission, exposure to infected body fluids or contaminated objects by small droplets through…
Read More
FDA approves Crizotinib for Myofibroblastic Tumors
The US FDA approves crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over 1 year of…
Read More
Dabrafenib Trametinib approved for metastatic tumors with BRAF V600E mutation
The US FDA has approved dabrafenib + trametinib for adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with the BRAF V600E mutation whose…
Read More
FDA approves Setmelanotide for obesity in Bardet-Biedl Syndrome
The US FDA has approved Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is the first FDA-approved therapy for BBS, a rare genetic disorder that impairs a hunger signal along the melanocortin-4…
Read More
Massive breakthrough as rectal cancer disappears in every patient in drug trial
Patients with locally advanced rectal cancer and tumors with deficient mismatch repair (dMMR) have shown a remarkable response to treatment with the programmed cell death-1 (PD-1) inhibitor dostarlimab (Jemperli). So…
Read More
IN.PACT 018 Drug-Coated Balloon approved for PAD
The US FDA has approved the IN.PACT 018 drug-coated balloon (DCB) for the treatment of peripheral arterial disease. The paclitaxel-coated balloon is indicated for percutaneous transluminal angioplasty of de novo,…
Read More
First Line for Esophageal Cancer is now Immunotherapy
Immunotherapy with nivolumab (Opdivo) is now approved in the United States for first-line use in the treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). The new approval…
Read More
Rare monkeypox detected in UK: Check symptoms, treatment & other details
A patient was found to be infected with monkeypox virus in the United Kingdom, who traveled to the country from Nigeria. Monkeypox is caused by monkeypox virus, a member of…
Read More
Saliva test for diagnosing endometriosis
The prospective ENDO-miRNA study included saliva samples obtained from women with chronic pelvic pain suggestive of endometriosis. Exploratory procedures were performed to look for lesions. All the patients underwent either…
Read More
FDA approves new immunotherapy for metastatic melanoma
The FDA approved a combination nivolumab/relatlimab-rmbw immune checkpoint inhibitor (Opdualag) for unresectable or metastatic melanoma in adults and children 12 years or older. Dose: 480 mg nivolumab + 160 mg…
Read More
FDA approves Anifrolumab as first new Lupus treatment in more than 10 years
Anifrolumab, an inhibitor of type 1 interferons, received approval from the Food and Drug Administration for the treatment of adults with moderate to severe systemic lupus erythematosus (SLE) who are…
Read More
First drug for cold agglutinin disease
The US FDA approves first drug for Cold Agglutinin Disease. Sutimlimab-jome (Brand name: ENJAYMO) is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion…
Read More
First treatment for rare Uveal Melanoma
The drug is tebentafusp-tebn (Kimmtrak, from Immunocore Limited), which acts as a bispecific gp100 peptide-HLA-directed CD3 T-cell engager. It is the first of a novel class of T-cell receptor (TCR)…
Read More
Vitamin D supplementation did not decrease the risk of cancer or CVD
Vitamin D supplementation did not appear to influence the incidence of cancer or major cardiovascular disease (CVD) events in older adults who largely already had adequate vitamin D levels, according…
Read More
FDA approves Cabotegravir ER Injectable for HIV PrEP
The FDA issued approval for extended-release injectable cabotegravir (Apretude, CAB-LA) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce…
Read More
FDA approves Efgartigimod for Myasthenia Gravis
The US FDA has approved efgartigimod (Brand name: Vygart) a first-in-class, targeted therapy for adults with generalized myasthenia gravis (gMG) who test positive for the antiacetylcholine receptor (AChR) antibody. Efgartigimod…
Read More
Abrocitinib approved for Atopic Dermatitis in Europe
The oral Janus kinase 1 inhibitor abrocitinib has been approved in Europe for the treatment of moderate to severe atopic dermatitis (AD) in adults, who are candidates for systemic therapy.…
Read More
FDA approves PreHevbrio: The first 3-antigen HBV vaccine for adults
PreHevbrio : contains the S, pre-S2, and pre-S1 HBV surface antigens, and is the only approved 3-antigen HBV vaccine for adults in the U.S.A. INDICATIONS AND USAGE: PREHEVBRIO is indicated…
Read More
New AKI risk score for PCI patients passes validation
A pair of updated scoring models for estimating a patient's risk for contrast-associated acute kidney injury during and immediately after percutaneous coronary intervention (PCI) worked better than a widely used…
Read More
FDA expands Pembrolizumab approval for Advanced Melanoma
The US Food and Drug Administration has approved pembrolizumab (Keytruda) for the adjuvant treatment of stage IIB and IIC melanoma after complete resection in adults and children over age 12…
Read More
Definitions for SARS-CoV-2 Variant of Interest & Variant of Concern
WHO has working definitions for SARS-CoV-2 Variant of Interest (VOI) and Variant of Concern (VOC). A SARS-CoV-2 VOI is a SARS-CoV-2 variant with genetic changes that are predicted or known…
Read More
Omicron: A variant of concern
WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). It is not yet clear whether Omicron…
Read More
The case of the ‘Esperanza patient’ whose HIV infection vanished naturally
Researchers have reported that a woman living with HIV in Argentina is now the second person whose immune system rid itself of the virus. She was diagnosed with HIV-1 in…
Read More
FDA approves Vosoritide for children with Achondroplasia
The US FDA has approved vosoritide (Voxzogo) daily injection for the treatment of children with achondroplasia. Indicated to increase linear growth in pediatric patients aged ≥5 years who have achondroplasia…
Read More
FDA approves ropeginterferon for adults with polycythemia vera
The U.S. FDA approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells. The excess cells thicken the…
Read More
FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations
The US FDA has granted an accelerated approval to mobocertinib for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor…
Read More
Novel diabetic foot ulcer cream shows promise in phase 3 trial
ON101 (Fespixon, Oneness Biotech), a first-in-class, macrophage-regulating, wound-healing cream for diabetic foot ulcers has shown benefit over absorbent dressings in a phase 3 trial, with another trial ongoing. The published…
Read More
Subcutaneous Inj. vedolizumab appears to be effective maintenance therapy in IBD-UC
Subcutaneous vedolizumab appears to be an effective and safe maintenance therapy for some patients with moderate to severe active Crohn's disease, according to results of a phase-3 trial. Vedolizumab, the…
Read More
FDA approves first vagus nerve stimulation system for stroke rehab
The US FDA has approved the Vivistim System (MicroTransponder), a first-of-its kind vagus nerve stimulation (VNS) system intended to treat moderate-to-severe upper extremity motor deficits associated with chronic ischemic stroke.…
Read More
Dapagliflozin might reduce the risk for ventricular arrhythmias in HFrEF
The addition of dapagliflozin to standard therapy reduced the relative risk for the primary composite endpoint of any serious ventricular arrhythmia, resuscitated cardiac arrest, or sudden death by 21%. Dapagliflozin…
Read More
FDA approves Brivaracetam for seizures in children as young as 1 Month
The approval covers all three brivaracetam (BRIVIACT) formulations (tablets, oral solution, and IV) and marks the first time the IV formulation will be available for children. Dosage: Dose for adults…
Read More
FDA approves TAVR System in severe AS
The US Food and Drug Administration has approved Medtronic's Evolut FX system for transcatheter aortic valve replacement (TAVR) in patients with symptomatic severe aortic stenosis at all risk levels. The…
Read More
FDA approves new indication for Rivaroxaban in PAD
The US FDA has approved an expanded peripheral artery disease (PAD) indication for the direct oral anticoagulant rivaroxaban to include patients who have undergone recent lower-extremity revascularization due to symptomatic…
Read More
Bimekizumab approved in Europe for Psoriasis treatment
Bimekizumab (Bimzelx), a humanized IgG1 monoclonal antibody, is the first approved treatment for moderate to severe plaque psoriasis that selectively inhibits interleukin (IL)–17A and IL-17F. Dose: 320 mg, given in…
Read More
FDA has expanded indication for the noninvasive Deep TMSTM
The US Food and Drug Administration (FDA) has expanded indication for the noninvasive BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMSTM) System to include treatment of comorbid anxiety symptoms in adult…
Read More
Microscopic lung damage may continue in ‘Long COVID’
The persistent breathing issues that plague some COVID-19 survivors, known as 'long COVID,' may be due to microscopic processes that continue to damage lungs even after the acute infection is…
Read More
A new monoclonal antibody named CIS43LS prevents malaria in new trial
A new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to 9 months in people who were exposed to the malaria parasite.…
Read More
Icotinib is the best adjuvant chemotherapy for EGFR-mutant NSCLC
Icotinib is a highly selective, first-generation EGFR tyrosine kinase inhibitor (TKI) approved in China as first-line monotherapy in patients with NSCLC with somatic EGFR mutations. Following complete resection of EGFR-mutant…
Read More
Physicians wearing white coats rated more experienced
Physicians wearing white coats were rated as significantly more experienced and professional than peers wearing casual attire. Regardless of their attire, however, female physicians were more likely to be judged…
Read More
New guideline for replacement of ART: CAB/RPV LA not for everyone
Approved by the FDA in late January 2021, CAB/RPV LA (cabotegravir/rilpivirine) is considered an optimization strategy for individuals with HIV whose virus is suppressed by oral ART and who might…
Read More
Restoring pulmonary endothelial cells reverses emphysema in mice
Correcting endothelial dysfunction in both human tissue and an elastase-induced murine model of emphysema shows promise in stopping and reversing the course of the disease, according to an international group…
Read More
New investigational helmet device shrinks glioblastoma
A case report describes a novel helmet device that generates a noninvasive oscillating magnetic field and that shrunk a glioblastoma tumor by about a third. The patient had end-stage recurrent…
Read More
Delta variant of COVID-19 as contagious as chickenpox
Internal Centers for Disease Control and Prevention (CDC) documents support the high transmission rate of the delta variant and put the risk in easier to understand terms. The documents also…
Read More
Lenvatinib plus Gefitinib therapy promising in liver cancer
In patients with advanced liver cancer who were unresponsive to lenvatinib, adding gefitinib (an EGFR inhibitor) led to a clinically meaningful response in a proof-of-concept study. 12 patients with advanced…
Read More
Urinary thromboxane B2 may be marker of aggressive prostate cancer in black men
Upregulation of urinary thromboxane B2 may be a new marker of aggressive prostate cancer in African American men, a group that bears a disproportionately high burden of lethal prostate cancer.…
Read More
Corneal changes may signal long COVID
Nerve fiber loss and an increase in dendritic or key immune cells on the cornea may help identify Long COVID, according to a small study published online today in the…
Read More
Ficlatuzumab + chemo shows early promise in refractory AML
The combination of ficlatuzumab plus chemotherapy showed considerable early promise in relapsed/refractory acute myeloid leukemia (AML) in a small phase-1 study. Ficlatuzumab is an investigational, first-in-class monoclonal antibody that binds…
Read More
FDA approves spinal cord stimulation for diabetic neuropathy pain
The Food and Drug Administration has approved the first high-frequency spinal cord stimulation (SCS) therapy for treating painful diabetic neuropathy (PDN). The approval is specific for the treatment of chronic…
Read More
China’s first human infection case with Monkey B virus dies
A Beijing-based veterinarian who was confirmed as China's first human infection case with Monkey B virus (BV) has died. The 53-year-old male vet, who worked for an institution researching on…
Read More
Three new drugs linked with ANCA-associated vasculitis
The overactive bladder treatment mirabegron (Myrbetriq) is one of three new drugs to be linked to cases of drug-associated antineutrophil cytoplasmic antibody-associated vasculitis (DA-AAV) according to pharmacovigilance data. The other…
Read More
New drugs for migraine
Five recently approved acute migraine treatments were specifically noted: two small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists — rimegepant and ubrogepant — along with the nonsteroidal anti-inflammatory drug celecoxib, the…
Read More
Prasugrel better than Ticagrelor in ACS patients undergoing PCI
The ISAR-REACT 5 trial has demonstrated the superiority of prasugrel to ticagrelor for patients presenting with ACS. Ticagrelor and prasugrel are both potent inhibitors of the P2Y12 receptor, but their…
Read More
FDA approves Finerenone for slowing CKD in T2DM
The FDA approved the anti-mineralocorticoid agent finerenone (Kerendia) for slowing the progression of chronic kidney disease in type 2 diabetes patients. The first non-steroidal, selective mineralocorticoid receptor antagonist was approved…
Read More
Lenvatinib-Pembrolizumab combo promising in advanced kidney cancer
The combination of the multikinase inhibitor lenvatinib and the anti-PD-1 antibody pembrolizumab has "encouraging" antitumor activity and a manageable side effect profile and might be an option following immune-checkpoint inhibitor…
Read More
Study shows tocilizumab and sarilumab reduce COVID-19 deaths
Treating critically ill COVID-19 patients with arthritis drugs tocilizumab and sarilumab significantly improves survival rates and reduces the amount of time patients need intensive care. The immunosuppressive drugs, Actemra, also…
Read More
Insulin-Pramlintide combo improves type 1 diabetes control
A novel investigational coformulation of prandial insulin and pramlintide improves blood glucose control and reduces body weight in people with type 1 diabetes, early research suggests. The injectable product combines…
Read More
Adalimumab safe and effective in children with UC
Adalimumab is effective and well-tolerated in children with moderate-to-severe ulcerative colitis (UC), with "clinically meaningful" rates of clinical remission and response, including steroid-free remission and mucosal healing, according to results…
Read More
What’s best for diabetes after metformin? GRADE trial states
Liraglutide and insulin glargine outperformed glimepiride and sitagliptin as single add-on agents to metformin for treating patients with type 2 diabetes in a multicenter US trial that randomized just over…
Read More
Hepatitis C antivirals may fight SARS-CoV-2
Sofosbuvir/ledipasvir and nitazoxanide both appeared to clear SARS-CoV-2, the virus that causes COVID-19 in a preliminary trial, said Mohamed Medhat, lecturer in the department of gastroenterology and tropical medicine at…
Read More
EC approves Cemiplimab for advanced or metastatic BCC after HHI therapy
The European Commission (EC) has approved cemiplimab (Libtayo) for the treatment of adults with locally advanced or metastatic basal cell carcinoma (BCC) who progressed on or could not tolerate treatment…
Read More
FDA approves first oral anticoagulant for children
The US Food and Drug Administration (FDA) has approved dabigatran etexilate (Pradaxa) oral pellets for the treatment of venous thromboembolism (VTE) in children aged 3 months to less than 12…
Read More
FDA approves StrataGraft for deep skin burns
The US FDA has approved a novel regenerative therapy that could be an alternative to autografting for treating adults with severe burns. The new treatment, StrataGraft, is a bilayer tissue-engineered…
Read More
‘COVID Toes’ Chilblain-like lesions not related to COVID-19
Chilblain-like lesions seen in adolescents during the COVID-19 pandemic are nonischemic and not related to systemic or localized SARS-CoV-2 infection, suggests a case series from Italy. These lesions "most likely…
Read More
Saliva test to detect HPV-associated throat cancer
A novel saliva test has been shown to detect HPV-associated oropharyngeal squamous cell carcinoma (OPSSC) with high accuracy in a small study. If the results are validated in subsequent studies,…
Read More
Noninvasive ventilation tied to higher mortality than CPAP in COVID-19 Pneumonia
Compared with continuous positive airway pressure (CPAP), the use of non-invasive ventilation (NIV) to treat acute respiratory failure secondary to COVID-19 pneumonia is tied to higher mortality, according to a…
Read More
FDA approves Brincidofovir to treat smallpox
The US FDA has approved Chimerix's brincidofovir (BCV, Tembexa) to treat smallpox. Fearful of a possible bioweapon attack, the United States has been steadily preparing a defense through the Biomedical…
Read More
FDA approves new drug treatment for chronic weight management
The US FDA approved Wegovy (semaglutide) injection a GLP-1 receptor agonists (2.4 mg once weekly SC) for chronic weight management in adults with obesity or overweight with at least one…
Read More
Gene variant confirmed as strong predictor of lung disease in RA
Patients with rheumatoid arthritis who carry a specific allele of the gene MUC5B have about double the risk of developing interstitial lung disease when compared with noncarriers, according to a…
Read More
Use belimumab after rituximab in patients with SLE
Using belimumab after rituximab to treat patients with systemic lupus erythematosus (SLE) refractory to conventional therapy not only significantly decreased levels of serum IgG anti-dsDNA antibody levels but also prolonged…
Read More
Toripalimab improves survival in nasopharyngeal cancer
Toripalimab is a monoclonal antibody that blocks programmed cell death protein 1 (PD-1), developed in China and recently approved there for the third-line treatment of NPC, among other indications. The…
Read More
India variant shows resistance to antibody drugs & vaccines
Antibody drugs and COVID-19 vaccines are less effective against a coronavirus variant that was first detected in India, researchers say. The variant, B.1.617.2, has mutations that make it more transmissible.…
Read More
Lifileucel promising against unresponsive malignant melanoma
Lifileucel shows promise in metastatic-melanoma patients whose disease had progressed on standard immune-checkpoint inhibitors (ICI) and other therapies, according to a small open-label trial. "Lifileucel is a ground-breaking form of…
Read More
FDA approves first drug for lung cancer with KRAS mutation
Sotorasib (Lumakras), specifically targets the KRAS G12C mutation, which accounts for about 13% of NSCLC mutations. KRAS mutations are the most common mutations to occur in NSCLC tumors, accounting for…
Read More
Hybrid therapy for H. pylori infection
A 14-day course of hybrid therapy was as effective as 10-day bismuth quadruple therapy, but with fewer side effects, according to results of a randomized trial conducted in Taiwan. In…
Read More
FDA approves Ozanimod for Ulcerative Colitis
The US FDA has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced. Ozanimod (0.92 mg), an oral medication taken once daily,…
Read More
Mild cortisol excess increases mortality in adrenal incidentaloma
Mortality is two to three times higher in patients with adrenal incidentalomas who have autonomous cortisol secretion levels of 83 nmol/L (3 µg/dL) or more after a 1 mg dexamethasone…
Read More
A novel drug most effective in sickest HFrEF patients
The greatest relative benefit from omecamtiv mecarbil, a novel myotropic drug class that improves cardiac performance, is produced in heart failure patients with the lowest left ventricular ejection fraction (LVEF),…
Read More
Sotagliflozin improves clinical outcomes in patients with HFpEF
The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve clinical outcomes in patients with heart failure…
Read More
Management protocol for Mucormycosis by AIIMS Rishikesh
Management by Inj Liposomal amphotericin B (LAmB): Test dose •Inj. Liposomal Amphotericin- B 1 vial (50 mg) to be diluted in 12 ml of the diluent and 0.25ml (1 mg)…
Read More
Novel IL-6 antibody reduces CRP up to 92% in High-risk ASCVD
Inhibition of interleukin (IL)-6 with ziltivekimab reduces multiple biomarkers of inflammation and thrombosis in patients at high atherosclerotic risk with moderate to severe chronic kidney disease (CKD) and elevated C-reactive…
Read More
Antibody status & incidence of SARS-CoV-2 infection in health care workers
The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. The presence of anti-spike or anti-nucleocapsid IgG…
Read More
ICMR releases guidelines for COVID-19 associated Mucormycosis
The correlation between COVID-19 and Mucormycosis isn't surprising, as the biggest risk factors are uncontrolled diabetes and immune suppressant steroids. Rhino-orbital-cerebral and pulmonary infections are the most common syndromes caused…
Read More
Statins: A potential treatment in COVID-19?
In the HARP-2 trial of simvastatin in acute respiratory distress syndrome (ARDS), published a few years ago, the main results were neutral, but in the subgroup of patients with hyperinflammatory…
Read More
Trastuzumab Deruxtecan has promising activity in Advanced Colorectal Cancer
Trastuzumab deruxtecan, an antibody-drug conjugate, showed "promising and durable activity" in HER2-positive metastatic colorectal cancer (CRC) refractory to standard treatment in an open-label phase-2 trial. HER2 amplification is seen in…
Read More
Varenicline nasal spray trial for Dry Eye
An experimental varenicline nasal spray can reduce signs and symptoms of dry eye disease, the results of a phase 3 trial suggest. That's because Oyster Point's OC-01 works by stimulating…
Read More
DCGI gives emergency approval of DRDO-developed anti-COVID oral drug
The Institute of Nuclear Medicine and Allied Sciences (Inmas) in collaboration with Dr Reddy’s Laboratories, Hyderabad, developed an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG). The third phase of…
Read More
Four months TB regimen
A new drug combination containing rifapentine and moxifloxacin has finally broken the 6-month treatment barrier for drug-susceptible pulmonary tuberculosis, requiring only 4 months to produce a disease-free state at 1…
Read More
Torsemide over Furosemide as first line Loop Diuretic for HF
Three reasons why consider torsemide should be considered a first-line treatment for heart failure. In a trial published in 2001, researchers randomized 234 patients with heart failure to receive torsemide…
Read More
New oral protein shows promise for Ulcerative Colitis
A plant-based fusion protein is safe and effective for inducing favorable immune modulation in patients with mild to moderate ulcerative colitis with no immune suppression–side effects reported. OPRX-106, an orally…
Read More
ECMO support in COVID-19 patients with refractory ARDS
COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO) appear to have a much lower mortality rate than initial early reports suggested. ECMO has been utilized in COVID-19 patients with acute…
Read More
FDA approves Dapagliflozin for Chronic Kidney Disease
The US Food and Drug Administration (FDA) has approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in…
Read More
Tralokinumab gets nod for Atopic Dermatitis in Europe
European Medicines Agency (EMA) issued a positive opinion for the IL-13 inhibitor tralokinumab (Adtralza) for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are eligible for systemic therapy.…
Read More
DCGI approves Virafin, Pegylated Interferon alpha-2b for COVID-19
Zydus Cadila announced that it has received restricted emergency use approval from the Indian drug regulator, Drug Controller General of India (DCGI), for the use of ‘Virafin’, Pegylated Interferon alpha-2b…
Read More
Role of Azithromycin in COVID-19
Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. Azithromycin might increase the pH of the…
Read More
Ublituximab + Ibrutinib for CLL
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease associated with several known genetic abnormalities, including 17p deletion (del), 11q deletion (del), and TP53 gene mutations, which are adverse prognostic…
Read More
FDA approves oral contraceptive with new estrogen
The novel combined oral contraceptive, marketed as Nextstellis, contains 3 mg drospirenone (DRSP) and 14.2 mg of estetrol (E4) in tablet form. Estetrol is an estrogen that is naturally produced…
Read More
New benznidazole treatment regimen for Chagas Disease shows promise
For treatment of Chagas disease, benznidazole can be taken for a shorter period of time and at lower doses with similar efficacy to the current standard regimen and is much…
Read More
Antibiotics in development not enough to tackle superbugs: WHO
None of the 43 antibiotics currently in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization…
Read More
What is the role of the antiviral drug remdesivir in the treatment of COVID-19?
Remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. It is indicated for treatment of COVID-19 disease in hospitalized adults and children aged 12 years and…
Read More
Brazil P1 coronavirus variant mutating is more dangerous
Brazil's P1 coronavirus variant, behind a deadly COVID-19 surge in the Latin American country that has raised international alarm, is mutating in ways that could make it better able to…
Read More
FDA approves first AI device to detect colon lesions
The US FDA announced its first-ever approval of an artificial intelligence device to help find colon lesions during colonoscopy. The GI Genius (Cosmo Artificial Intelligence) identifies areas of the colon…
Read More
Reactive Infectious Mucocutaneous Eruption associated with COVID-19
Formerly known as Mycoplasma-induced rash and mucositis, RIME has arisen as the preferred terminology to include mucocutaneous eruptions that are caused by other infectious agents. RIME secondary to SARS-CoV-2 infection,…
Read More
Volanesorsen shows promise in Multifactorial Chylomicronemia
Volanesorsen significantly reduces triglyceride levels in patients with multifactorial chylomicronemia syndrome and may reduce acute pancreatitis events in these patients, according to results of the COMPASS trial. In an earlier…
Read More
New HIV vaccine shows great results in phase 1 trial
The International AIDS Vaccine Initiative (IAVI) and Scripps Research have recently announced the results of an important Phase I clinical trial. The researchers tested a new vaccine approach designed to…
Read More
HCC risk reduced by aspirin in chronic viral hepatitis
HCC is the fourth-leading cause of cancer mortality worldwide, and is driven mostly by viral hepatitis B (HBV) and viral hepatitis C (HCV) infection. The risk of hepatocellular carcinoma (HCC)…
Read More
Chronic adverse events likely common after Anti-PD-1 therapy for Melanoma
Chronic immune-related adverse events (irAEs) associated with anti-programmed cell death-1 (PD-1) therapy for melanoma were more common than previously thought in a retrospective multicenter study. As reported in JAMA Oncology,…
Read More
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
When esophageal or gastroesophageal-junction cancer remains a threat after chemoradiotherapy and surgery because of residual pathological disease, treatment with the checkpoint inhibitor nivolumab doubles disease-free survival, according to the results…
Read More
BRCA1 & BRCA 2 mutations raise risk for Endometrial Cancer also
Women with a BRCA1 or BRCA2 mutation have an increased risk for endometrial cancer (EC), and the greatest risk is for the rare subgroup of serous-like and p53-abnormal endometrial cancers…
Read More
Quadruple medical therapy for Heart Failure
Quadruple therapy with an angiotensin receptor–neprilsyin inhibitor (ARNI), evidence-based β-blocker, mineralocorticoid receptor antagonist (MRA), and sodium glucose cotransporter 2 inhibitor (SGLT2i) may reduce risk of death by 73% over 2…
Read More
Higher calorie refeeding effective in teens with anorexia nervosa
Researchers examined data on adolescents (mean age 16.4 years) hospitalized with anorexia nervosa who were randomized to higher-calorie refeeding (n=60) or lower-calorie refeeding (n=51). Patients started higher-calorie refeeding (2,000 kcals/day,…
Read More
European Union approved Duvelisib for CLL and Follicular Lymphoma
European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines…
Read More
FDA approves neuromodulation device to improve gait in MS
The US FDA has approved the Portable Neuromodulation Stimulator for the short-term treatment of walking impairments as a result of mild to moderate symptoms from multiple sclerosis (MS). PoNS is…
Read More
FDA approves Transcatheter Pulmonary Valve for Congenital Heart Disease
The US FDA has approved Medtronic's Harmony Transcatheter Pulmonary Valve (TPV) System to treat severe pulmonary regurgitation in pediatric and adult patients who have a native or surgically repaired right…
Read More
A new genetic mutation in schizophrenia discovered
The discovery of this new gene, PCDHA3, could enhance the development of genetic-risk calculators "that may help us understand vulnerability to schizophrenia in high-risk individuals and identify individuals with schizophrenia…
Read More
FDA warns abuse of OTC decongestant potentially deadly
Abuse or misuse of the over-the-counter nasal decongestant propylhexedrine can cause serious harm that can lead to hospitalization, disability, or death, the US Food and Drug Administration (FDA) warns in…
Read More
A 6 month multidrug regimen for MDR-TB trial is successful
The trial, called TB PRACTECAL, compared the current local standard of care with a six-month regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin. The interim analysis included 242 patients and the…
Read More
FDA approves new ready to inject glucagon product
The US FDA has approved dasiglucagon (Zegalogue 0.6 mg/0.6 mL, Zealand Pharma) autoinjector and prefilled syringe for the treatment of severe hypoglycemia in people with diabetes aged 6 and older.…
Read More
Double mutant variant of the coronavirus has been detected in India
A new "double mutant" variant of the coronavirus has been detected from samples collected in India. Officials are checking if the variant, where two mutations come together in the same…
Read More
Menopausal hormone therapy curbs nocturia by improving sleep
Hormone therapy as a possible solution for postmenopausal women with nocturia. A significant reduction in prevalence of nocturia ≥ twice per night was seen after treatment, as the prevalence decreased…
Read More
IDSA updates COVID-19 treatment guidelines
The Infectious Diseases Society of America (IDSA) continues to examine available and potential treatments as new evidence emerges. Combination use of the monoclonal antibodies bamlanivimab and etesevimab to treat outpatients…
Read More
Interesting case of Ocular vicarious menstruation in India
A 25-year-old married woman recently went to the emergency room at a hospital in Chandigarh, India after she experienced haemolacria (crying tears of blood). Interestingly, she wasn’t in any pain…
Read More
Ertugliflozin, the (SGLT2) inhibitor has renal benefits also
Ertugliflozin, the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, now has shown evidence of renal benefits roughly on par with the other three drugs. Treatment of patients with type 2 diabetes…
Read More
Omidubicel improves on umbilical cord blood transplants
Omidubicel, an investigational enriched umbilical cord blood product being developed by Gamida Cell for transplantation in patients with blood cancers, appears to have some advantages over standard umbilical cord blood.…
Read More
CDC & WHO establish new threat levels for COVID-19 variants
The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have established new criteria to classify variants of SARS-CoV-2, the virus that causes COVID-19. The criteria…
Read More
Roche is launching a SARS-CoV-2 variant test
Roche is launching a SARS-CoV-2 variant test to help monitor emerging coronavirus mutations. The test runs on widely used high-throughput systems and is for research purposes only. The new SARS-CoV-2…
Read More
Weight gain linked to HP Dysfunction in pediatric brain tumor survivors
Children who have been treated for brain tumors often experience significant weight gain, and new findings suggest that this could be a sign of hypothalamic-pituitary (HP) dysfunction. The Dutch study…
Read More
BASILICA technique prevents TAVR related coronary obstruction
The acronym BASILICA stands for bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction. In the procedure, performed immediately before TAVR, guidewires are introduced to the…
Read More
Major update of BP Guidance for CKD, Treat to 120 mmHg
The new 2021 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for blood pressure management for adults with CKD who are not receiving dialysis advises treating to a target…
Read More
FDA warns against using Ivermectin to treat COVID-19
The US FDA has issued guidance warning consumers against using the antiparasitic drug ivermectin to treat or prevent COVID-19. The agency issued the guidance in light of growing interest in…
Read More
FDA approves a new oral stimulant medication for ADHD
The US FDA has approved a new, once-daily oral stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. Azstarys (KemPharm, Inc)…
Read More
New oral antiviral appears to stop SARS-CoV-2 in five days
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants. Preclinical studies suggest that molnupiravir is effective…
Read More
New blood test predicts risk of organ rejection after kidney transplant
IL-10 to TNFα Ratio: Strong predictor of rejection found in the blood. A total of 244 kidney transplant recipients from the University of Pittsburgh School of Medicine participated in the…
Read More
A novel therapy for Schizophrenia
KarXT - a novel combination of xanomeline with trospium. A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis…
Read More
Researchers have discovered a new type of bone cells “osteomorphs”
Researchers have discovered a new type of bone cells, called "osteomorphs," which may be targeted for osteoporosis and other skeletal diseases. The discovery came when Dr. Tri Giang Phan of…
Read More
More disappointing results for Vitamin C, Thiamine & Hydrocortisone in Sepsis
Among critically ill patients with sepsis, treatment with hydrocortisone, vitamin C (ascorbic acid) and thiamine (HAT) did not improve outcome in the randomized controlled VICTAS trial. The VICTAS trial enrolled…
Read More
FDA approves treatment for rare Duchenne Muscular Dystrophy Mutation
The U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the…
Read More
Russia detects first case of H5N8 bird flu in humans
The H5N8 strain is deadly for birds, and this marks the first transmission of the strain from animals to humans and has reported the matter to the World Health Organization…
Read More
Zika vaccine candidate shows promise in Phase 1 Trial
The researchers randomized 100 healthy adult volunteers to an experimental Zika vaccine candidate known as Ad26.ZIKV.001 in either one-dose or two-dose regimens of 5x1010 viral particles (low dose) or 1x1011…
Read More
FDA: COVID-19 not transmitted by food or packaging
"After more than a year since the coronavirus disease 2019 (COVID-19) outbreak was declared a global health emergency, the U.S. Department of Agriculture, the U.S. Food and Drug Administration and…
Read More
Tocilizumab cuts deaths in hospitalized COVID-19 patients
Tocilizumab, sold under the brand name Actemra, is an intravenous anti-inflammatory monoclonal antibody drug used to treat rheumatoid arthritis. It was added to the trial in April 2020 for patients…
Read More
FDA approves Evinacumab-dgnb for Homozygous familial hypercholesterolemia
The US FDA has approved the fully human monoclonal antibody evinacumab-dgnb (Evkeeza, Regeneron Pharmaceuticals) for use on top of other cholesterol-modifying meds in patients aged 12 and older with homozygous…
Read More
Pembrolizumab ‘Preferred Choice’ in MSI-H/dMMR Metastatic CRC
Pembrolizumab significantly improved progression-free survival compared with chemotherapy among patients with microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer, according to results from the KEYNOTE-177 study. Study Details: The KEYNOTE-177 trial…
Read More
Ruxolitinib as second line drug in Chronic GVHD
Ruxolitinib, a JAK inhibitor first marketed for use in myelofibrosis, is already approved for acute GVHD. The US Food and Drug Administration approved that indication last year on the basis…
Read More
Human to human transmission of Chapare virus in Bolivia
Chapare hemorrhagic fever (CHHF) is a viral hemorrhagic fever caused by infection with Chapare virus. The Chapare virus is in the arenavirus family. Arenaviruses are usually spread to people through…
Read More
VEXAS Syndrome
Researchers from the National Institutes of Health (NIH) have discovered a new inflammatory disorder called Vacuoles, E1 enzyme, X-linked, Autoinflammatory and somatic Syndrome (VEXAS), which is caused by mutations in…
Read More
Protein predicts risk of AKI in COVID-19 patients
Levels of a specific protein Soluble urokinase plasminogen activator receptor (suPAR) produced by immune cells predicts a very high risk of AKI. Median suPAR level 60% higher in patients with…
Read More
Endoscopic Sleeve Gastroplasty safe, Effective for obesity over 5 years
Endoscopic sleeve gastroplasty (ESG) was safe and effective for weight loss, during a single-centre five-year follow-up study. "It is a great procedure, patients are satisfied, and it achieves good results,"…
Read More
FDA approves Somapacitan-beco for Adult Growth Hormone Deficiency treatment
FDA approves Sogroya (somapacitan-beco) a 0nce-weekly treatment for Adult Growth Hormone Deficiency. Sogroya (somapacitan-beco) injection 10 mg/1.5 mL (6.7 mg/mL) is a human growth hormone analog taken once a week…
Read More
Antihypertensive drugs that reduces risk for Depression
The risk of depression is elevated in patients with cardiovascular diseases, but several specific antihypertensive therapies are associated with reduced risk, and none appear to increase the risk, according to a…
Read More
FDA approves saliva test to detect COVID-19
FDA approves emergency use of Saliva Test to detect COVID-19 Rutgers University-based RUCDR Infinite Biologics developed a saliva collection method in partnership with Spectrum Solutions and Accurate Diagnostic Labs. The…
Read More
CO-RADS classification
The CO-RADS classification is a standardized reporting system for patients with suspected COVID-19 infection developed for a moderate to high prevalence setting. CO-RADS 1 COVID-19 is highly unlikely. The CT…
Read More
Sintilimab + Platinum based chemotherapy in Advanced Nonsquamous NCLC
The investigational anti-PD-1 antibody sintilimab has shown that it improves the efficacy of platinum-based chemotherapy in the first-line treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC) in…
Read More
BCG vaccination may slow spread of COVID-19
Countries that had compulsory bacillus Calmette-Guérin (BCG) vaccination at least until 2000 appear to have built up a degree of “herd immunity” against COVID-19, a new study suggests. BCG vaccination…
Read More
Tenofovir prophylaxis to prevent mother-to-child transmission of HBV
New recommendation: WHO recommends that pregnant women testing positive for HBV infection (HBsAg positive) with an HBV DNA ≥ 5.3 log10 IU/mL (≥ 200,000 IU/mL)1 receive tenofovir prophylaxis from the…
Read More
Lenvatinib-Pembrolizumab combination in Advanced Gastric Cancer
The combination of the anti-PD-1 antibody pembrolizumab and the multikinase inhibitor lenvatinib provides objective response rates in many patients with advanced gastric cancer, according to results from an early single-arm…
Read More
COVID-19 coronavirus vaccine tracker
Researchers worldwide are working around the clock to find a vaccine against SARS-CoV-2, the virus causing the COVID-19 pandemic. Experts estimate that a fast-tracked vaccine development process could speed a…
Read More
FDA approves Collagenase Clostridium Histolyticum for Cellulite
The FDA has approved collagenase clostridium histolyticum for the treatment of moderate to severe cellulite in the buttocks of adult women. The drug is the first injectable treatment for cellulite…
Read More
Cutaneous manifestations of COVID-19
Observed COVID-19 associated skin patterns were: Acral erythema with vesicles or pustules; so-called "pseudo-chilblains" or "COVID Toes" (19%) Vesicular (chicken pox-like) eruptions (9%) Maculopapular eruptions (47%) Urticaria (19%) Livedo or…
Read More
Triple therapy for COPD
Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single-dose levels of…
Read More
WHO warns of oxygen shortage as COVID cases set to 10 million
The world faces a shortage of oxygen concentrators as the number of worldwide cases of coronavirus infection nears the 10 million. COVID-19 Tracker › “Many countries are now experiencing difficulties…
Read More
Gilead prices Remdesivir at $2,340 for a five-day treatment
Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from…
Read More
FDA approves atezolizumab + bevacizumab for advanced HCC
The US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have…
Read More